<DOC>
	<DOCNO>NCT00839631</DOCNO>
	<brief_summary>This Phase 1 , dose escalation study evaluate safety pharmacokinetics enteric coat D-3263 HCl subject advance solid tumor</brief_summary>
	<brief_title>Dose Escalation Study EC D-3263 HCl Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>histologically cytologically confirm advanced solid tumor malignancy either refractory standard therapy standard therapy exist measurable evaluable disease &gt; = 18 year age ECOG 0 , 1 2 treatement chemotherapy , radiotherapy systemic therapy ( exclude depot LHRH agonist antagonist subject prostate cancer ) treatment tumor 28 day prior receipt EC D3263 HCl Clinically significant coronary artery disease conduction system abnormality Coagulation disorder Active infection require use systemic antimicrobial medication within seven day prior receipt EC D3263 HCl Any major surgery within 28 day prior receipt EC D3263 HCl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>subject advance solid tumor refractory standard therapy effective therapy available .</keyword>
</DOC>